Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study.
Journal: Breast cancer research and treatment
Published: January 04, 2021
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Journal: The Lancet. Oncology
Published: September 03, 2019
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
Journal: The New England journal of medicine
Published: June 06, 2017
Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
Journal: Cancer chemotherapy and pharmacology
Published: October 27, 2016
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Journal: The New England journal of medicine
Published: February 19, 2015
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
Journal: The Lancet. Oncology
Published: April 23, 2013
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Journal: The New England journal of medicine
Published: December 14, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026